In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cyclo Therapeutics (CYTH – Research Report), with a price target of $10.00. The company’s shares opened today at $2.16.
McCarthy covers the Healthcare sector, focusing on stocks such as Biocept, Plus Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -38.8% and a 14.16% success rate on recommended stocks.
Currently, the analyst consensus on Cyclo Therapeutics is a Moderate Buy with an average price target of $10.00.
See the top stocks recommended by analysts >>
CYTH market cap is currently $18.77M and has a P/E ratio of (1.22).
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CYTH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Read More on CYTH:
- Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Syros Pharmaceuticals (SYRS)
- Orca Energy Group Inc. notes announcement by Swala Oil and Gas (Tanzania) PLC
- AstraZeneca’s stock is well suited for long-term growth
- JMP Securities Remains a Buy on Syros Pharmaceuticals (SYRS)
- Ceva (CEVA) Receives a Rating Update from a Top Analyst
